Baseline telomere length and effects of a multidomain lifestyle intervention on cognition: the FINGER randomized controlled trial

Manuscript Number: 

17-0123R1

Author(s): 
Riitta Antikainen, Iiris Hovatta, Tuomo Hänninen, Dharma S. Khalsa, Miia Kivipelto, Ingemar Kåreholt, Tiina Laatikainen, Esko Levälahti, Jaana Lindström, Tiia Ngandu, Teemu Paajanen, Markku Peltonen, Shireen Sindi, Hilkka Soininen, Alina Solomon, Timo E. Strandberg, Jaakko Tuomilehto, Benjamin Wolozin

Disclosures

Riitta Antikainen

  • Nothing to Disclose

Tuomo Hänninen

  • Nothing to Disclose

Iiris Hovatta

  • Nothing to Disclose

Ingemar Kåreholt

  • Nothing to Disclose

Dharma S. Khalsa

  • Sponsors:
    I am medical director of The Alzheimers Research and Prevention Foundation ( a non-profit not a commercial entity) that helped fund the FINGER study. I helped with the telomere aspect.

Miia Kivipelto

  • Nothing to Disclose

Tiina Laatikainen

  • Nothing to Disclose

Esko Levälahti

  • Nothing to Disclose

Jaana Lindström

  • Nothing to Disclose

Tiia Ngandu

  • Nothing to Disclose

Teemu Paajanen

  • Nothing to Disclose

Markku Peltonen

  • Nothing to Disclose

Shireen Sindi

  • Nothing to Disclose

Hilkka Soininen

  • Consulting Fees:
    ACImmune for Consulting.

Alina Solomon

  • Nothing to Disclose

Timo E. Strandberg

  • Consulting Fees:
    Occasional in various companies, minor amount.
    Lecture Fees:
    Occasional in various companies, minor amount.

Jaakko Tuomilehto

  • Nothing to Disclose

Benjamin Wolozin

  • Consulting Fees:
    I am CSO for Aquinnah Pharmaceuticals Inc., and the structure of the payments is as a consultant.
    Equity:
    Aquinnah Pharmaceuticals Inc., Co-Founder, 40% of the equity.
    Patents/Royalties
    5 patents, one patent application. The two most recent include: Wolozin, B., Identification of Compounds that disperse TDP-43 inclusions. Patent Application. PCT/US12/38861 (2012). 2015 Wolozin, B., Nucleic acid based TIA1 inhibitors. Application #: 62/241535